hyaluronic acid + chondroitin sulphate + aluminium hydroxide + omeprazole

This is an **oral combination** of **hyaluronic acid**, **chondroitin sulphate**, **aluminium hydroxide**, and **omeprazole**. - **Hyaluronic acid** is a high molecular weight glycosaminoglycan primarily used for its lubricating, anti-inflammatory, and tissue regenerative properties, acting mainly through CD44 receptor binding. - **Chondroitin sulphate** is a slow-acting symptomatic drug for osteoarthritis, often combined with other agents, and supports cartilage structure via interactions in the extracellular matrix. Both HA and CS modulate cartilage damage and inflammation, partly by inhibiting NF-κB pathway activation, leading to decreased release of inflammatory mediators and reduced extracellular matrix degradation[1][3][5]. - **Aluminium hydroxide** is an antacid that neutralizes gastric acid by direct chemical reaction, providing symptomatic relief in conditions such as dyspepsia and gastroesophageal reflux disease. - **Omeprazole** is a small molecule proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme in gastric parietal cells, blocking gastric acid secretion and used in peptic ulcer disease, GERD, and other hypersecretory conditions[8]. The combination likely targets joint health (HA + CS) and gastric protection (aluminium hydroxide + omeprazole), with typical use in situations where both symptomatic osteoarthritis management and gastric protection are clinically required. No unique trade name for this exact four-drug combination is identified in the literature; combinations of HA, CS, and antacid/PPI are used to minimize NSAID-related gastropathy while addressing osteoarthritis symptoms[7].